These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 25496414)
1. Experiences of UK patients with hepatitis C virus infection accessing phlebotomy: A qualitative analysis. Clements A; Grose J; Skirton H Nurs Health Sci; 2015 Jun; 17(2):214-22. PubMed ID: 25496414 [TBL] [Abstract][Full Text] [Related]
2. Jugular venipuncture and other innovative approaches to phlebotomy among people who inject drugs. Ferguson C; Higgs P; Olsen A Nurs Health Sci; 2015 Dec; 17(4):539-41. PubMed ID: 26306397 [TBL] [Abstract][Full Text] [Related]
3. "It gives me a sense of belonging": providing integrated health care and treatment to people with HCV engaged in a psycho-educational support group. Woolhouse S; Cooper E; Pickard A Int J Drug Policy; 2013 Nov; 24(6):550-7. PubMed ID: 23860471 [TBL] [Abstract][Full Text] [Related]
4. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. Swan D; Long J; Carr O; Flanagan J; Irish H; Keating S; Keaveney M; Lambert J; McCormick PA; McKiernan S; Moloney J; Perry N; Cullen W AIDS Patient Care STDS; 2010 Dec; 24(12):753-62. PubMed ID: 21138381 [TBL] [Abstract][Full Text] [Related]
5. The lived experience of hepatitis C and its treatment among injecting drug users: qualitative synthesis. Treloar C; Rhodes T Qual Health Res; 2009 Sep; 19(9):1321-34. PubMed ID: 19690211 [TBL] [Abstract][Full Text] [Related]
6. Venous access and care: harnessing pragmatics in harm reduction for people who inject drugs. Harris M; Rhodes T Addiction; 2012 Jun; 107(6):1090-6. PubMed ID: 22151433 [TBL] [Abstract][Full Text] [Related]
7. Views and experiences of hepatitis C testing and diagnosis among people who inject drugs: systematic review of qualitative research. Jones L; Atkinson A; Bates G; McCoy E; Porcellato L; Beynon C; McVeigh J; Bellis MA Int J Drug Policy; 2014 Mar; 25(2):204-11. PubMed ID: 24332457 [TBL] [Abstract][Full Text] [Related]
8. The common sense model applied to hepatitis C: a qualitative analysis of the impact of disease comparison and witnessed death on hepatitis C illness perception. Safo SA; Batchelder A; Peyser D; Litwin AH Harm Reduct J; 2015 Jun; 12():20. PubMed ID: 26092261 [TBL] [Abstract][Full Text] [Related]
9. The politics of place(ment): problematising the provision of hepatitis C treatment within opiate substitution clinics. Rance J; Newland J; Hopwood M; Treloar C Soc Sci Med; 2012 Jan; 74(2):245-53. PubMed ID: 22133583 [TBL] [Abstract][Full Text] [Related]
11. The drugs that dare not speak their name: Injecting and other illicit drug use during treatment for hepatitis C infection. Hopwood M; Treloar C Int J Drug Policy; 2007 Oct; 18(5):374-80. PubMed ID: 17854725 [TBL] [Abstract][Full Text] [Related]
12. Client and staff experiences of a co-located service for hepatitis C care in opioid substitution treatment settings in New South Wales, Australia. Treloar C; Rance J; Grebely J; Dore GJ Drug Alcohol Depend; 2013 Dec; 133(2):529-34. PubMed ID: 23932843 [TBL] [Abstract][Full Text] [Related]
13. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals. Treloar C; Newland J; Rance J; Hopwood M J Viral Hepat; 2010 Dec; 17(12):839-44. PubMed ID: 20070504 [TBL] [Abstract][Full Text] [Related]
14. Impact of a positive hepatitis C diagnosis on homeless injecting drug users: a qualitative study. Tompkins CN; Wright NM; Jones L Br J Gen Pract; 2005 Apr; 55(513):263-8. PubMed ID: 15826432 [TBL] [Abstract][Full Text] [Related]
15. Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty. Rhodes T; Davis M; Judd A Addiction; 2004 May; 99(5):621-33. PubMed ID: 15078237 [TBL] [Abstract][Full Text] [Related]
16. Factors associated with hepatitis C knowledge among a sample of treatment naive people who inject drugs. Treloar C; Hull P; Bryant J; Hopwood M; Grebely J; Lavis Y Drug Alcohol Depend; 2011 Jul; 116(1-3):52-6. PubMed ID: 21194852 [TBL] [Abstract][Full Text] [Related]
17. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. Sutton AJ; Gay NJ; Edmunds WJ; Hope VD; Gill ON; Hickman M BMC Infect Dis; 2006 Jun; 6():93. PubMed ID: 16762050 [TBL] [Abstract][Full Text] [Related]
18. Receiving a hepatitis C-positive diagnosis. Hopwood M; Treloar C Intern Med J; 2004; 34(9-10):526-31. PubMed ID: 15482264 [TBL] [Abstract][Full Text] [Related]
19. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Doab A; Treloar C; Dore GJ Clin Infect Dis; 2005 Apr; 40 Suppl 5():S313-20. PubMed ID: 15768340 [TBL] [Abstract][Full Text] [Related]
20. Discrimination by health care workers versus discrimination by others: countervailing forces on HCV treatment intentions. Brener L; Horwitz R; von Hippel C; Bryant J; Treloar C Psychol Health Med; 2015; 20(2):148-53. PubMed ID: 24889417 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]